JDD February 2023 Issue Highlights
The February issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, case reports, and brief communications exploring topics such as efficacy and safety of 1% clascoterone cream in patients aged ≥12 years with acne vulgaris, dupilumab’s impact on atopic dermatitis among adolescent and adult patients, development and validation of a photonumeric scale …
Applying the Psoriasis Guidelines to Practice
psoriasis guidelinesNext Steps in Derm and the Journal of Drugs in Dermatology, in partnership with the Dermatology Education Foundation (DEF) and Physicians Resources,  interviewed Dr. April Armstrong (Professor of Dermatology and Associate Dean for Clinical Research at the Keck School of Medicine at USC) on applying the psoriasis guidelines established by the American Academy of Dermatology and the National Psor …
psoriasis guidelines
Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy
Tofacitinib INTRODUCTION Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib …
Tofacitinib
The Full Spectrum of Dermatology: A Diverse And Inclusive Atlas Launches New, Free Online Image Gallery
Inclusive dermatology atlas online gallery "The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas" announces expansion of its educational reach with a digital online free image gallery. The inclusive dermatology atlas online image gallery provides more than 800 images of 110 commonly diagnosed dermatologic conditions in an array of skin tones, including skin of color, and compliments the print atlas which was first released …
Inclusive dermatology atlas online gallery
Pop Quiz #202
The correct answer is A. Autoimmune regulator (AIRE). Autoimmune polyendocrinopathy-candidiasis–ectodermal dystrophy (APECED) syndrome is named for the clinical features of autoimmune polyendocrinopathy, candidiasis, and ectodermal dystrophy. It is caused by a mutation in AIRE (autoimmune regulator). Nearly 13% of these patients have vitiligo. APECED is also known as autoimmune polygland …
error

Enjoy this blog? Please spread the word :)